NCEL NewcelX Ltd.
Price Chart
Executive Summary
NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy) combined with tegoprubart for type 1 diabetes, with a Type B pre-IND meeting scheduled for late June 2026. This is an early-stage regulatory milestone for a clinical-stage company with a $17M market cap, but no financial data, guidance, or near-term revenue catalyst is provided.
Actionable Insight
Pre-IND meeting is a procedural step with binary outcome risk; no revenue or catalyst date until IND clearance and trial initiation. Monitor FDA feedback post-June meeting and any subsequent financing needs given going concern warning. Stock may see speculative volatility but lacks fundamental catalyst until clinical data emerges.
Key Facts
- Pre-IND briefing package submitted to FDA for NCEL-101 + tegoprubart combination in type 1 diabetes.
- Type B pre-IND meeting scheduled for last week of June 2026.
- NCEL-101 is an enriched stem cell-derived islet product candidate; tegoprubart is an investigational anti-CD40L antibody from Eledon Pharmaceuticals (ELDN).
- Supported by 12-patient investigator-initiated study at University of Chicago Medicine showing preserved islet function with tegoprubart.
- Tegoprubart has been used in >100 transplant recipients across multiple FDA-cleared INDs.
- NewcelX is a clinical-stage regenerative medicine company with no approved products or disclosed revenue.
- Market cap is $17M; analyst consensus is 0% bullish (3 Hold, 1 Sell, 2 Strong Sell).
- Forward-looking statements note substantial doubt about going concern and Nasdaq listing compliance.
Financial Impact
No financial figures disclosed; pre-IND milestone with no revenue or cost data.
Risk Factors
- Going concern risk noted in forward-looking statements — company may need dilutive financing.
- Nasdaq listing compliance risk — potential delisting if market cap or bid price issues persist.
- Pre-IND meeting outcome uncertain; FDA may require additional preclinical data delaying timeline.
- No approved products or revenue; clinical-stage biotech with binary event risk.
- Analyst consensus heavily bearish (0% bullish) with 3 Hold, 3 Sell/Strong Sell.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
9d ago
|
6-K
| $3.07 awaiting T+5 | awaiting T+5 | — | $3.23 (+5.21%) |
|
May 27, 2026
18d ago
|
Press Release
| $3.45 $3.32 | ▼ −3.77% | ▼ −4.98% | $3.23 (−6.38%) |
|
May 18, 2026
28d ago
|
EFFECT
| $3.11 $3.15 | ▼ −1.29% | ▲ +0.33% | $3.23 (−3.86%) |
|
May 7, 2026
5w ago
|
EFFECT
| $3.24 $3.24 | · 0.00% | ▼ −1.50% | $3.23 (−0.31%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $4.41 $3.32 | ▲ +24.72% | ▲ +26.44% | $3.23 (+26.76%) |
|
Apr 20, 2026
7w ago
|
6-K
| $2.83 $3.87 | ▲ +36.75% | ▲ +35.84% | $3.23 (+14.13%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $2.83 $3.87 | ▲ +36.75% | ▲ +35.84% | $3.23 (+14.13%) |
|
Apr 1, 2026
10w ago
|
6-K
| $2.26 $2.49 | ▲ +10.42% | ▲ +6.80% | $3.23 (+43.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access